Specialty pharmaceutical company for prescription medicines and medical diagnostic products.
Kowa Pharmaceutical Europe Co. Ltd.
United KingdomNew on Amplifa
About Kowa Pharmaceutical Europe
Kowa Pharmaceutical Europe Co. Ltd. is a specialty pharmaceutical company based in the United Kingdom and a division of Japan's Kowa Company, Ltd., a multinational group with diverse manufacturing and trading activities. The company markets prescription medicines as well as medical diagnostic products such as non-mydriatic retinal cameras, portable retinal cameras, software and refraction devices. Its therapeutic focus areas include lifestyle-related diseases (dyslipidemia, type 2 diabetes, arteriosclerosis), inflammatory and immune diseases, and sensory organ disorders, particularly eye and hearing conditions. Research and development are concentrated at the Tokyo New Drug Research Laboratories and the Fuji Laboratory in Japan. In Europe, the lipid-lowering product Livazo is distributed through the partner Recordati. In fiscal year March 2025, the Kowa Group generated group revenue of ¥556,923 million with 8,074 employees and 108 key subsidiaries.
- Site
- United Kingdom
- Processes
- Research & Development, Distribution of prescription medicines, Distribution of medical diagnostic products (retinal cameras, software, refraction)
- Employees
- 8074
- Industries
- Pharmaceutical Industry, Medical Technology/Diagnostics, Healthcare
- 01
Research & Development
- 02
Regulatory Approval
- 03
Distribution of Prescription Medicines
- 04
Distribution of Medical Diagnostic Products
Products
Inside the production
Industries
Additional services
History
- 2009
Kowa and Brigham and Women's Hospital (Harvard University) opened the Center for Interdisciplinary Cardiovascular Sciences (CICS)
- 2025
Pemafibrate (K-808) received FDA 'Breakthrough Therapy' designation for primary biliary cholangitis; group revenue of ¥556,923 million and 8,074 employees (March 2025)